Latest Articles

Publication Date
Metabolic Enzyme ME1 Emerges as Key to Unlocking Progestin Therapy in Endometrial Cancer - Bioengineer.org

Metabolic Enzyme ME1 Emerges as Key to Unlocking Progestin Therapy in Endometrial Cancer Bioengineer.org

Published: Sept. 30, 2026, 10:09 p.m.
Metabolic Enzyme ME1 Emerges as Key to Unlocking Progestin Therapy in Endometrial Cancer - bioengineer.org

Metabolic Enzyme ME1 Emerges as Key to Unlocking Progestin Therapy in Endometrial Cancer bioengineer.org

Published: Sept. 30, 2026, 10:09 p.m.
Depot medroxyprogesterone acetate and the risk for developing an intracranial meningioma.

Several investigations have reported on the increased risk of meningioma following depot medroxyprogesterone acetate (DMPA) treatment. An extensive PubMed search was conducted evaluate systematic reviews, propensity-matched studies and case-control studies …

Published: Sept. 21, 2026, midnight
Presumed Hippocampal Endometriosis Presenting as Catamenial Epilepsy: Diagnostic Challenges, MRI Follow-Up, and Comparative Review of Reported Cerebral Endometriosis Case.

Background: Cerebral endometriosis is an exceptionally rare manifestation of extrapelvic endometriosis and remains a diagnostic challenge because its clinical and imaging features may mimic more common neurological, inflammatory, vascular, or …

Published: Sept. 11, 2026, midnight
Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies.

Endometriosis is frequently managed with hormonal suppression that can induce hypoestrogenism during a period when many patients are still accruing peak bone mass. This narrative review summarizes current clinical and …

Published: Aug. 19, 2026, midnight
Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.

Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …

Published: Aug. 11, 2026, midnight
Exploring New Treatment Strategies for Endometriosis-Narrative Review.

The pharmacological treatment of endometriosis using SPRMs requires improvement. The pure PR-agonist dienogest (DNG), a clinically established progestin, can serve as a reference compound for comparison. Its efficacy and safety …

Published: July 28, 2026, midnight
GnRH Analogues for the Treatment of Endometriosis-Related Pain: A Narrative Review.

Endometriosis is a chronic estrogen-dependent condition affecting women of reproductive age and commonly presents with dysmenorrhea, chronic pelvic pain, dyspareunia, and infertility. In a substantial proportion of patients, pain persists …

Published: July 11, 2026, midnight
PGRMC1 suppression enhances progesterone responsiveness in stromal cells of ovarian endometrioma.

Progesterone resistance in endometriosis reduces the efficacy of progestin. The non-classical progesterone receptor, progesterone receptor membrane component 1 (PGRMC1) may regulate progesterone signaling in the normal endometrium, but its expression …

Published: July 6, 2026, midnight
Preserved large elastic arterial stiffness and impaired conduit artery endothelial function in patients with endometriosis receiving progestin therapy: A cross-sectional observational study.

To evaluate central arterial stiffness, endothelial function, and circulating vascular biomarkers in women with ovarian endometriosis and to explore their associations compared with age-matched controls.

Published: July 3, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!